These findings elucidated that the combination therapy with EGFR inhibitors might synergistically enhance the anti-HNSCC capacity and attenuate the resistance to EGFR therapy, and further experimental work is needed to verify this hypothesis. This evidence concerns the gene EGFR and head and neck squamous cell carcinoma.